<DOC>
	<DOCNO>NCT00866645</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety Intramuscular Levosulpiride treatment Chinese patient Agitation Of Schizophrenia compare Intramuscular Haloperidol evaluate change PANSS-EC total score end study ( 72 hour first dose ) baseline .</brief_summary>
	<brief_title>A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of Schizophrenia</brief_title>
	<detailed_description>Secondary Outcome Measures : To evaluate change Agitation Calmness Evaluation Scale ( ACES ) , Clinical Global Impression ( CGI , include CGI-S CGI-I ) , PANSS total score , Brief Psychiatric Rating Scale ( BPRS ) total score every item PANSS-EC baseline end study ( Time Frame : 72 hour ) [ Designated safety issue : No ] To evaluate change patient ' main complain , physical examination , lab ECG test , AE、Rating Scale Extrapyramidal Side Effect ( RSESE ) Barnes Akathisia Scale ( BAS ) baseline end study ( Time Frame : 72 hour ) [ Designated safety issue : Yes ]</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>Male female Chinese inpatient ( require stay hospital study ) age 1865 year Patients meet DSMIV criterion schizophrenia schizophreniform psychosis Agitated minimum total score ≧ 15 five item PANSSEC least one individual item score ≧ 5 two item score ≧ 4 use 17 score system ACES≤3 Written inform consent provide patient ' legal representative Investigator his/her relatives Participation another drug trial within 3 month prior enrolment study Female patient pregnant lactation period Any currently severe unstable medical illness disease would affect assessment study , include epilepsy , angle closure glaucoma , disease liver , kidney , gastrointestinal tract , respiratory system , cardiovascular system ( include Ischemic Heart Disease ) , endocrine system , nervous system , immune hematological system etc . A significantly clinical abnormal value ECG lab result , ALT AST value liver function test exceed two time upper limit normal value , urea nitrogen value arise 1.2 time upper limit normal value , creatinine serum potassium exceed normal value With family history sudden death Meet DSMIV criterion substance abuse within 1 year prior enrolment Regularly use antipsychotic ( clozapine within 90 day ) , antidepressant , mood stabilizer , antiepileptic prolongedaction preparation within 2 week prior enrolment Use Electroconvulsive therapy within 30 day prior enrolment Systematically use sulpiride , levosulpiride haloperidol therapy within 30 day prior enrolment History current neuroleptic malignant syndrome , severe EPS , significant tardive dyskinesia Severe suicide attempt Known hypersensitivity sulpiride , levosulpiride haloperidol , history severe drug hypersensitivity hypersensitivity 2 drug Use psychotropics ( except permit drug ) within 12 hour prior enrolment Known lack efficacy levosulpiride haloperidol formal treatment Organic mental disorder , include Mental retardation History psychosurgery treatment Patients comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Agitation</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Randomized</keyword>
	<keyword>Blind</keyword>
	<keyword>Parallel</keyword>
	<keyword>Intramuscular Haloperidol</keyword>
	<keyword>Controlled</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Intramuscular Levosulpiride</keyword>
	<keyword>Chinese</keyword>
	<keyword>PANSS-EC</keyword>
	<keyword>ACES</keyword>
	<keyword>CGI</keyword>
	<keyword>BPRS</keyword>
	<keyword>PANSS</keyword>
	<keyword>RSESE</keyword>
	<keyword>BAS</keyword>
</DOC>